Related Experiment Video
Updated: Apr 15, 2026
10:29
A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
8.4K
Tuberculosis: An Inorganic Medicinal Chemistry Perspective
Livia Viganor, Ciaran Skerry, Malachy McCann
1College of Sciences and Health, Dublin Institute of Technology, Kevin Street, Dublin 8, Ireland. michael.devereux@dit.ie.
Current Medicinal Chemistry
|April 9, 2015
Summary
Metal complexes show promise as novel treatments for tuberculosis (TB), offering new mechanisms of action against drug-resistant Mycobacterium tuberculosis strains. This review explores their potential to overcome limitations of current TB therapies.
Area of Science:
- Medicinal Inorganic Chemistry
- Antimicrobial Drug Discovery
Background:
- Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), is a growing global health concern.
- Increasing multi-drug resistant (MDR) and extensively drug-resistant (XDR) MTB strains challenge conventional therapies.
- Current anti-TB treatments are lengthy, toxic, and have side effects.
Purpose of the Study:
- To review the antitubercular capabilities of metal complexes.
- To explore their mechanisms of action.
- To speculate on their clinical applications.
Main Methods:
- Literature review of existing research on metal complexes and their anti-TB activity.
- Analysis of inorganic medicinal chemistry approaches for TB drug development.
- Discussion of structure-activity relationships and potential novel mechanisms.
Main Results:
- Metal complexes offer diverse structural possibilities and oxidation states for drug design.
- Coordination to metal centers can enhance the activity of existing organic drugs.
- Inorganic compounds present an alternative therapeutic strategy targeting different biochemical pathways.
Conclusions:
- Metal complexes represent a promising avenue for developing new anti-TB drugs.
- They offer potential to overcome resistance and improve treatment efficacy.
- Further research into their clinical application is warranted.
More Related Videos
Related Concept Videos
01:28Pulmonary Tuberculosis V
926
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
926
01:26Pulmonary Tuberculosis IV
751
Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
751
01:28Pulmonary Tuberculosis II
2.3K
Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
2.3K
01:31Pulmonary Tuberculosis III
1.6K
Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
The first classification is based on the development of the disease, and it includes the following categories:
1.6K
01:29Pulmonary Tuberculosis I
1.5K
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
1.5K
01:27Combined Effects of Drugs: Synergism
8.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
8.0K